Autologous, Engineered T Cells Targeting Tp53 R248Q
Other Solid Tumor
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Other Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rucaparib pharmaand GmbH | Phase 3 | B |
Brigatinib Princess Maxima Center for Pediatric Oncology | Phase 1/2 | CCC |
Same molecule, other indications
Autologous, Engineered T Cells Targeting Tp53 R248Q is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →